Clinical Trials
Sponsor:
Sponsor Study ID:
Study Title:
A Randomized, Double blind, Placebo Controlled, Active Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects with Relapsed or Refractory Diffuse Large B cell Lymphoma (DLBCL)
NCT Number:
NCT04404283
Phase:
III
Protocol Type:
Treatment
Age Group:
Adults
Disease Sites:
Non-Hodgkin's Lymphoma
Study Objectives:
This study is being done to see if adding brentuximab vedotin helps two drugs work better to treat patients with diffuse large B-cell lymphoma (DLBCL). Participants in this study will have DLBCL that has come back or not gotten better with treatment.
Study Documents
(MUSC NetID required for document access)